Eric Bjerkholt
CHIEF FINANCIAL OFFICER; Director · 9 filings · Latest: Jun 9, 2026
CERUS CORP
Metagenomi Therapeutics, Inc.
Mirum Pharmaceuticals, Inc.
Surrozen, Inc./DE
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
CERS | Eric Bjerkholt | Director | Jun 9, 2026 | Sale | $2.60 | 20,454 | $53.2K | 261,679 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jun 9, 2026 | Option Exercise | $26.49 | 2,393 | $63.4K | 47,181 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale | $93.82 | 5,000 | $469.1K | 44,788 | |
CERS | ERIC BJERKHOLT | — | Jun 9, 2026 | Proposed Sale | $2.60 | 20,454 | $53.2K | — | |
MIRM | ERIC BJERKHOLT | — | Jun 8, 2026 | Proposed Sale | $93.81 | 5,000 | $469.1K | — | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Mar 16, 2026 | Sale | $91.98 | 7,287 | $670.2K | 49,788 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Mar 15, 2026 | Option Exercise | — | 13,334 | — | 57,075 | |
MIRM | ERIC BJERKHOLT | — | Mar 16, 2026 | Proposed Sale | $92.64 | 7,287 | $675.1K | — | |
MIRM | ERIC BJERKHOLT | — | Jan 26, 2026 | Proposed Sale | $96.92 | 1,053 | $102.1K | — | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jan 26, 2026 | Sale | $96.19 | 1,053 | $101.3K | 43,741 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jan 23, 2026 | Option Exercise | — | 2,667 | — | 44,794 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jan 22, 2026 | Sale | $93.33 | 1,421 | $132.6K | 42,127 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jan 21, 2026 | Option Exercise | — | 3,334 | — | 43,548 | |
CERS | BJERKHOLT ERIC | — | Dec 12, 2024 | Proposed Sale | $1.79 | 20,000 | $35.7K | — |